Depletion of Eg5 using ASO treatment in CaP and LNCaP prostate cancer cell lines reduced both Eg5 mRNA and Eg5 protein levels, resulting in dose-dependent growth inhibition, G2/M arrest and apoptosis. This evidence concerns the gene KIF11 and prostate carcinoma.